MED MEDIFAST INC
Miscellaneous Food Preparations & Kindred Products · NYSE · SEC CIK 910329 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-30.3%
TTM net income YoY-16,572.6%
TTM EPS YoY-18,600.0%
Revenue 3-yr CAGR-37.4%
Net income 3-yr CAGR—
Margins
Gross margin69.2%
Operating margin-11.6%
Net margin-13.6%
FCF margin-1.3%
EBITDA margin-7.4%
Returns
ROE-20.7%
ROA-16.1%
ROIC (approx.)-23.2%
Asset turnover1.18x
Leverage & solvency
Liabilities / assets24.8%
Debt / equity0.00x
Current ratio4.82x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.00x
Accruals ratio-16.1%
Payout ratio—
Capex / revenue1.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $385.79M | $602.46M |
| Cost of revenue | $110.60M | $157.84M |
| Gross profit | $275.19M | $444.62M |
| R&D expense | $4.30M | $4.60M |
| SG&A expense | $289.40M | $441.75M |
| Operating income | -$14.21M | $2.88M |
| Pretax income | -$5.64M | $3.79M |
| Income tax | $13.03M | $1.70M |
| Net income | -$18.67M | $2.09M |
| EBITDA | $29,000 | $15.59M |
| EPS (basic) | -1.70 | 0.19 |
| EPS (diluted) | -1.70 | 0.19 |
| Dividends declared per share | 0.00 | 0.00 |
| Weighted avg. shares (diluted) | 10.98M | 10.96M |
| Balance sheet | ||
| Cash & equivalents | $89.30M | $90.93M |
| Short-term investments | $77.97M | $71.42M |
| Inventory | $20.23M | $42.42M |
| Current assets | $201.68M | $214.40M |
| PP&E, net | $31.23M | $37.53M |
| Total assets | $247.97M | $284.21M |
| Current liabilities | $42.96M | $64.16M |
| Total liabilities | $49.05M | $74.10M |
| Shareholders' equity | $198.92M | $210.11M |
| Shares outstanding | 10.99M | 10.94M |
| Cash flow statement | ||
| Operating cash flow | $6.86M | $24.48M |
| Capital expenditure | $5.61M | $7.45M |
| Free cash flow | $1.25M | $17.02M |
| Investing cash flow | -$7.93M | -$26.52M |
| Financing cash flow | -$564,000 | -$1.51M |
| Depreciation & amortization | $14.24M | $12.71M |
| Stock-based compensation | $7.64M | $7.36M |
| Dividends paid | $195,000 | $715,000 |
| Share buybacks | $0 | $0 |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.